SINGAPORE: US pharmaceutical company AbbVie on Thursday (Sep 29) opened a new S$400 million manufacturing facility in Tuas Biomedical Park, its first manufacturing plant in Asia.
The Chicago-based firm is expected to hire more than 250 employees for the 120,000-sqm plant, which comprises AbbVie's small molecule active pharmaceutical ingredients (API) facility and a biologics manufacturing facility.
The company chose to set up a base in Singapore because of its "robust infrastructure" and "highly educated and skilled workforce", as well as its supportive environment for manufacturing, said AbbVie site director Marc O'Donoghue.
"Our presence in Singapore established AbbVie's footprint in Asia and provides geographic balance in AbbVie's manufacturing network to ensure continuity of supply," he added.
The API facility has begun operations, while the biologics facility is expected to be fully operational by 2018.
Speaking at the launch, Trade and Industry Minister (Industry) S Iswaran reiterated the importance of the healthcare industry as a growth sector for Singapore.
"To support the continued growth of our biopharmaceutical manufacturing sector, the Government has adopted a multi-pronged strategy. It focuses on catalysing innovation in manufacturing technologies, developing infrastructural solutions, and building a strong talent pool," he said.